HAE - Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
2025-05-10 13:05:28 ET
Haemonetics Corporation (HAE)
Q4 2025 Earnings Conference Call
May 08, 2025 8:00 AM ET
Company Participants
Olga Guyette – Vice President-Investor Relations & Treasury
Chris Simon – Chief Executive Officer
James D'Arecca – Chief Financial Officer
Conference Call Participants
Rohin Patel – JPMorgan
Marie Thibault – BTIG
Mike Matson – Needham & Company
Andrew Cooper – Raymond James
Joanne Wuensch – Citi
Anthony Petrone – Mizuho Financial Group
Michael Petusky – Barrington Research
Craig Bijou – Bank of America Securities
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to turn the conference over to Olga Guyette, Vice President Investor Relations and Treasury. Please go ahead.
Olga Guyette
Good morning, and thank you all for joining us for Haemonetics fourth quarter and fiscal year 2025 conference call and webcast. I'm joined today by Chris Simon, our CEO; and James D'Arecca, our CFO.
This morning, we posted our fourth quarter and fiscal year 2025 results to our Investor Relations website, along with additional supplemental tables that support some of the assumptions within our fiscal year 2026 guidance included in our earnings release. These supplemental tables help reconcile the projected fiscal year 2026 growth rate of electrophysiology, coronary and peripheral procedures in the U.S. with the corresponding exercise opportunities for our Vascular Closure business. The exercise opportunities represent the anticipated growth of the U.S. addressable market in Vascular Closure as incorporated in our Hospital and total company revenue guidance for fiscal year 2026.
Before we begin, just a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise and exclude the impact of currency fluctuations, acquisitions and impact of the Whole Blood divestiture. We'll also refer to other non-GAAP financial measures to help investors understand Haemonetics ongoing business performance.
Please note that these measures exclude certain charges and income items. A full list of excluded items, reconciliations to our GAAP results and comparisons with the prior year periods are provided in our fourth quarter fiscal year 2025 earnings release available on our website.
Our remarks today include forward-looking statements, and our actual results may differ materially from anticipated results. Factors that may cause our results to differ include those referenced in the safe harbor statement in today's earnings release and in our other SEC filings. We do not undertake any obligation to update these forward-looking statements....
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript